The IPCEI was signed to address the need to equip Europe with a strong, innovative and export-friend...
Read moreAn affordable and sustainable market access landscape is key to ensure patient access to life-saving...
Read moreThe draft final guidance reverses previous guidance issued in November 2021 rejecting the drug for r...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreBased on a recent decision by the Interministerial Commission on Medicines Prices offering a price l...
Read moreWe explore why combination pricing is an issue in the oncology space and why payers and manufacturer...
Read moreThe study looks at the direct, indirect and mortality-related costs of 24 rare diseases across five ...
Read moreThe National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s Zej...
Read moreOn 28th February 2022, Health and Social Care Secretary Sajid Javid launched England’s first Rare...
Read moreThe National Recovery and Resilience Plan had extended the membership to the CPR and CTS until 28th...
Read more